Daratumumab (DARA) is the biological name of an Immunoglobulin G1k human monoclonal antibody. DARA the first-in-class therapy targeting CD38 expressing- plasma cells (PC) and plasma blasts. It has been approved for the treatment of multiple myeloma. It is also being examined in the setting of...
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent...
Daratumumab, carfilzomib, lenalidomide and dexamethasone (dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134(suppl 1): 860. doi: ...
This treatment is not approved for multiple myeloma yet, but it is being tested to see how safe it is and how well it works. CAR T stands for chimeric antigen receptor (CAR) T-cell therapy. Doctors take some of your blood and remove the T cells, which are considered workhorses of you...
Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myelomaCyrille TouzeauBenjamin HébraudXavier Leleu
yeloma: daratumumab 靶向CD38的治疗多发性骨髓瘤新药:达拉木单抗%A new drug targeting CD38 in treatment of multiple myeloma: daratumumab靶向CD38的治疗多发性骨髓瘤新药:达拉木单抗%A new drug targeting CD38 in treatment of multiple myeloma: daratumumab达拉木单抗...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Multiple myeloma (MM) remains incurable despite important recent advances in treatment. Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM. Early-stage clinical trials have found DARA to be safe and to ...
EP: 10.Multiple Myeloma Challenges and Treatment EvolutionThis is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP. Hinojosa explored treatment options beyond DRd (daratumumab, lenalidomide, dexamethasone), VRd (bortezomib, lenalidomide, dexamethasone), and KRd (carfilzomib...